Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches (2024)

1. Wirsching, Glioblastoma., Handb Clin Neurol, № 134, с. 381
   https://doi.org/10.1016/B978-0-12-802997-8.00023-2
2. Goodenberger, Genetics of adult glioma., Cancer Genet, № 205, с. 613
   https://doi.org/10.1016/j.cancergen.2012.10.009
3. Penas-Prado, Glioblastoma., Handb Clin Neurol, № 105, с. 485
   https://doi.org/10.1016/B978-0-444-53502-3.00004-5
4. D’Alessio, Pathological and molecular features of glioblastoma and its peritumoral tissue., Cancers (Basel), № 11, с. 469
   https://doi.org/10.3390/cancers11040469
5. Hanif, Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment., Asian Pac J Cancer Prev, № 18, с. 3
6. Roesler, Neuroinflammation and immunoregulation in glioblastoma and brain metastases: recent developments in imaging approaches., Clin Exp Immunol, № 206, с. 314
   https://doi.org/10.1111/cei.13668
7. Sharma, Tumor microenvironment in glioblastoma: current and emerging concepts., Neurooncol Adv, № 5, с. 1
8. Ghosh, The interplay of tumor vessels and immune cells affects immunotherapy of glioblastoma., Biomedicines, № 10, с. 2292
   https://doi.org/10.3390/biomedicines10092292
9. Galvão, Inflammation and gliomagenesis: bi-directional communication at early and late stages of tumor progression., Curr Pathobiol Rep, № 1, с. 19
   https://doi.org/10.1007/s40139-012-0006-3
10. Yuile, Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables., J Clin Neurosci, № 13, с. 747
    https://doi.org/10.1016/j.jocn.2005.10.011
11. Faivre, Clinical reasoning: worsening neurologic symptoms in a brain tumor patient., Neurology, № 85, с. e57
    https://doi.org/10.1212/WNL.0000000000001848
12. Batich, Long-term survival in glioblastoma with cytomegalovirus Pp65-targeted vaccination., Clin Cancer Res, № 23, с. 1898
    https://doi.org/10.1158/1078-0432.CCR-16-2057
13. Kanu, Glioblastoma multiforme oncogenomics and signaling pathways., Clin Med Oncol, № 3, с. 39
14. Medikonda, A review of glioblastoma immunotherapy., J Neurooncol, № 151, с. 41
    https://doi.org/10.1007/s11060-020-03448-1
15. Pop, Long non-coding RNAs in brain tumours: focus on recent epigenetic findings in glioma., J Cell Mol Med, № 22, с. 4597
    https://doi.org/10.1111/jcmm.13781
16. Poon, Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis., Brain, № 140, с. 1548
    https://doi.org/10.1093/brain/aww355
17. Yeo, The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy., Cells, № 10, с. 607
    https://doi.org/10.3390/cells10030607
18. DeCordova, Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma., Front Immunol, № 11, с. 1402
    https://doi.org/10.3389/fimmu.2020.01402
19. Chen, Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma., Front Immunol, № 13, с. 869307
    https://doi.org/10.3389/fimmu.2022.869307
20. Pearson, Targeting cellular pathways in glioblastoma multiforme., Signal Transduct Target Ther, № 2, с. 17040
    https://doi.org/10.1038/sigtrans.2017.40
21. Khabibov, Signaling pathways and therapeutic approaches in glioblastoma multiforme (review)., Int J Oncol, № 60, с. 69
    https://doi.org/10.3892/ijo.2022.5359
22. Vyas, Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis., Onco Targets Ther, № 7, с. 1015
    https://doi.org/10.2147/OTT.S60114
23. Zhao, Inflammation and tumor progression: signaling pathways and targeted intervention., Signal Transduct Target Ther, № 6, с. 263
    https://doi.org/10.1038/s41392-021-00658-5
24. Al-kharboosh, Inflammatory mediators in glioma microenvironment play a dual role in gliomagenesis and mesenchymal stem cell homing: implication for cellular therapy., Mayo Clin Proc Innov Qual Outcomes, № 4, с. 443
    https://doi.org/10.1016/j.mayocpiqo.2020.04.006
25. Greten, Inflammation and cancer: triggers, mechanisms and consequences., Immunity, № 51, с. 27
    https://doi.org/10.1016/j.immuni.2019.06.025
26. Doan, Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency., Oncotarget, № 8, с. 112662
    https://doi.org/10.18632/oncotarget.22637
27. Jaeckle, Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis., J Neurooncol, № 104, с. 253
    https://doi.org/10.1007/s11060-010-0476-2
28. Pangeni, The impact of epigenetic modifications on adaptive resistance evolution in glioblastoma., Int J Mol Sci, № 22, с. 8324
    https://doi.org/10.3390/ijms22158324
29. Appin, Molecular genetics of gliomas., Cancer J, № 20, с. 66
    https://doi.org/10.1097/PPO.0000000000000020
30. Darmanis, Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma., Cell Rep, № 21, с. 1399
    https://doi.org/10.1016/j.celrep.2017.10.030
31. Bayin, Glioblastoma stem cells: molecular characteristics and therapeutic implications., World J Stem Cells, № 6, с. 230
    https://doi.org/10.4252/wjsc.v6.i2.230
32. Lathia, Cancer stem cells in glioblastoma., Genes Dev, № 29, с. 1203
    https://doi.org/10.1101/gad.261982.115
33. Gilard, Diagnosis and management of glioblastoma: a comprehensive perspective., J Pers Med, № 11, с. 258
    https://doi.org/10.3390/jpm11040258
34. Zhang, Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy., Front Mol Biosci, № 7, с. 562798
    https://doi.org/10.3389/fmolb.2020.562798
35. Aldape, Glioblastoma: pathology, molecular mechanisms and markers., Acta Neuropathol, № 129, с. 829
    https://doi.org/10.1007/s00401-015-1432-1
36. Ideguchi, MRI findings and pathological features in early-stage glioblastoma., J Neurooncol, № 123, с. 289
    https://doi.org/10.1007/s11060-015-1797-y
37. Urbanska, Glioblastoma multiforme – an overview., Contemp Oncol (Pozn), № 18, с. 307
38. Derinkuyu, Primary intraspinal glioblastoma multiforme in a child., Spine J, № 15, с. e37
    https://doi.org/10.1016/j.spinee.2015.07.451
39. Mikkelsen, The histological representativeness of glioblastoma tissue samples., Acta Neurochir (Wien), № 163, с. 1911
    https://doi.org/10.1007/s00701-020-04608-y
40. Wang, Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction., CNS Neurosci Ther, № 25, с. 876
    https://doi.org/10.1111/cns.13120
41. Tichy, Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma., J Neurooncol, № 126, с. 361
    https://doi.org/10.1007/s11060-015-1978-8
42. Figueroa, Detection of glioblastoma in biofluids., J Neurosurg, № 129, с. 334
    https://doi.org/10.3171/2017.3.JNS162280
43. Hoelzinger, Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets., Neoplasia, № 7, с. 7
    https://doi.org/10.1593/neo.04535
44. Bacchi, Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review., Antiinflamm Antiallergy Agents Med Chem, № 11, с. 52
    https://doi.org/10.2174/187152312803476255
45. Alorfi, Pharmacological methods of pain management: narrative review of medication used., Int J Gen Med, № 16, с. 3247
    https://doi.org/10.2147/IJGM.S419239
46. Pountos, Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects., Int J Interf Cytokine Mediat Res, № 3, с. 19
47. Qiu, Cyclooxygenase-2 in glioblastoma multiforme., Drug Discov Today, № 22, с. 148
    https://doi.org/10.1016/j.drudis.2016.09.017
48. Gabriely, MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators., Mol Cell Biol, № 28, с. 5369
    https://doi.org/10.1128/MCB.00479-08
49. Lopes, Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth., Purinergic Signal, № 17, с. 273
    https://doi.org/10.1007/s11302-021-09775-w
50. Bai, Ibuprofen on proliferation and apoptosis of sarcoma cells via PI3K/Akt/MTOR signaling pathway., Cell Mol Biol (Noisy-le-grand), № 67, с. 73
    https://doi.org/10.14715/cmb/2021.67.5.10
51. Takahashi-Yanaga, The Wnt/β-catenin signaling pathway as a target in drug discovery., J Pharmacol Sci, № 104, с. 293
    https://doi.org/10.1254/jphs.CR0070024
52. Dietrich, Corticosteroids in brain cancer patients: benefits and pitfalls., Expert Rev Clin Pharmacol, № 4, с. 233
    https://doi.org/10.1586/ecp.11.1
53. Lee, Corticosteroids for peritumoral edema: time to overcome our addiction?, Neuro Oncol, № 18, с. 1191
    https://doi.org/10.1093/neuonc/now167
54. Cenciarini, Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies., Front Mol Neurosci, № 12, с. 448734
    https://doi.org/10.3389/fnmol.2019.00065
55. Pitter, Corticosteroids compromise survival in glioblastoma., Brain, № 139, с. 1458
    https://doi.org/10.1093/brain/aww046
56. Himes, Immunosuppression in glioblastoma: current understanding and therapeutic implications., Front Oncol, № 11, с. 770561
    https://doi.org/10.3389/fonc.2021.770561
57. Wharton, Medications that cause weight gain and alternatives in Canada: a narrative review., Diabetes Metab Syndr Obes, № 11, с. 427
    https://doi.org/10.2147/DMSO.S171365
58. Alonso-Diez, Anti-angiogenic treatments interact with steroid secretion in inflammatory breast cancer triple negative cell lines., Cancers (Basel), № 13, с. 3668
    https://doi.org/10.3390/cancers13153668
59. Zhou, The prognostic effect of dexamethasone on patients with glioblastoma: a systematic review and meta-analysis., Front Pharmacol, № 12, с. 2318
60. Mathios, Circulating biomarkers in glioblastoma: ready for prime time?, Cancer J, № 27, с. 404
    https://doi.org/10.1097/PPO.0000000000000541
61. Hentschel, Current surgical management of glioblastoma., Cancer J, № 9, с. 113
    https://doi.org/10.1097/00130404-200303000-00007
62. Seker-Polat, Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives., Cancers, № 14, с. 443
    https://doi.org/10.3390/cancers14020443
63. Lara-Velazquez, Advances in brain tumor surgery for glioblastoma in adults., Brain Sci, № 7, с. 166
    https://doi.org/10.3390/brainsci7120166
64. Kim, Impact of fluorescence-guided surgery on the improvement of clinical outcomes in glioblastoma patients., Neurooncol Pract, № 1, с. 81
65. Yano, Experimental curative fluorescence-guided surgery of highly invasive glioblastoma multiforme selectively labeled with a killer-reporter adenovirus., Mol Ther, № 23, с. 1182
    https://doi.org/10.1038/mt.2015.63
66. Shiroishi, Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma., Neuro Oncol, № 18, с. 467
    https://doi.org/10.1093/neuonc/nov179
67. Young, Current trends in the surgical management and treatment of adult glioblastoma., Ann Transl Med, № 3, с. 121
68. Mann, Advances in radiotherapy for glioblastoma., Front Neurol, № 8, с. 748
    https://doi.org/10.3389/fneur.2017.00748
69. Glaser, Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival., J Neurooncol, № 134, с. 107
    https://doi.org/10.1007/s11060-017-2493-x
70. Hanco*ck, The role of radiation therapy in the treatment of central nervous system tumors., Semin Oncol Nurs, № 20, с. 253
    https://doi.org/10.1016/S0749-2081(04)00089-0
71. McKelvey, Differential effects of radiation fractionation regimens on glioblastoma., Radiat Oncol, № 17, с. 1
    https://doi.org/10.1186/s13014-022-01990-y
72. Fuller, Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme., Radiat Oncol, № 2, с. 26
    https://doi.org/10.1186/1748-717X-2-26
73. Cruz, Highlighted advances in therapies for difficult-to-treat brain tumours such as glioblastoma., Pharmaceutics, № 15, с. 928
    https://doi.org/10.3390/pharmaceutics15030928
74. Carlson, Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials., J Neurooncol, № 123, с. 251
    https://doi.org/10.1007/s11060-015-1791-4
75. König, Glioblastoma radiotherapy using intensity modulated radiotherapy (IMRT) or proton radiotherapy—GRIPS trial (glioblastoma radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study., Radiat Oncol, № 16, с. 1
    https://doi.org/10.1186/s13014-021-01962-8
76. Lovo, Stereotactic radiosurgery for recurrent glioblastoma multiforme: a retrospective multi-institutional experience., Cureus, № 13, с. e18480
77. Prelaj, Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy., Mol Clin Oncol, № 10, с. 49
78. Kalra, A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus., Diabetes Ther, № 11, с. 1965
    https://doi.org/10.1007/s13300-020-00894-y
79. Møller, A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy., Acta Oncol, № 51, с. 797
    https://doi.org/10.3109/0284186X.2012.681063
80. Guo, Role of nanomedicine-based therapeutics in the treatment of CNS disorders., Molecules, № 28, с. 1283
    https://doi.org/10.3390/molecules28031283
81. Vinjamuri, Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients., J Neurooncol, № 91, с. 221
    https://doi.org/10.1007/s11060-008-9702-6
82. Tan, Management of glioblastoma: state of the art and future directions., CA Cancer J Clin, № 70, с. 299
    https://doi.org/10.3322/caac.21613
83. Herbener, Considering the experimental use of temozolomide in glioblastoma research., Biomedicines, № 8, с. 151
    https://doi.org/10.3390/biomedicines8060151
84. Ferri, Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma., Int J Mol Sci, № 21, с. 4910
    https://doi.org/10.3390/ijms21144910
85. Giese, Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma., J Neurooncol, № 66, с. 351
    https://doi.org/10.1023/B:NEON.0000014539.90077.db
86. Cellarier, Pharmaco*kinetic study of cystemustine, administered on a weekly schedule in cancer patients., Ann Oncol, № 13, с. 760
    https://doi.org/10.1093/annonc/mdf098
87. Parker, Molecular heterogeneity in glioblastoma: potential clinical implications., Front Oncol, № 5, с. 55
    https://doi.org/10.3389/fonc.2015.00055
88. Darakchiev, Safety and efficacy of permanent Iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme., J Neurosurg, № 108, с. 236
    https://doi.org/10.3171/JNS/2008/108/2/0236
89. Reithmeier, BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors., BMC Cancer, № 10, с. 1
    https://doi.org/10.1186/1471-2407-10-30
90. Brandes, A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme., Neurology, № 58, с. 1759
    https://doi.org/10.1212/WNL.58.12.1759
91. Woltjer, Neuropathologic effects of chemical warfare agents., Handb Toxicol Chem Warf Agents, с. 653
    https://doi.org/10.1016/B978-012374484-5.00043-2
92. Lyon, Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts., Transl Cancer Res, № 7, с. S802
    https://doi.org/10.21037/tcr.2018.08.19
93. Gil-Gil, Bevacizumab for the treatment of glioblastoma., Clin Med Insights Oncol, № 7, с. 123
    https://doi.org/10.4137/CMO.S8503
94. Kazazi-Hyseni, Bevacizumab., Oncologist, № 15, с. 819
    https://doi.org/10.1634/theoncologist.2009-0317
95. de Aguiar, Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors., Front Immunol, № 10, с. 1023
    https://doi.org/10.3389/fimmu.2019.01023
96. Iwamoto, Bevacizumab for malignant gliomas., Arch Neurol, № 67, с. 285
    https://doi.org/10.1001/archneurol.2010.11
97. Corr, Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy?, Gynecol Oncol Rep, № 17, с. 65
    https://doi.org/10.1016/j.gore.2016.06.002
98. Alahmari, Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of randomized controlled trials., Am Health Drug Benefits, № 9, с. 221
99. Yoshimoto, Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab., Ann Gastroenterol Surg, № 4, с. 151
    https://doi.org/10.1002/ags3.12312
100. Mecca, Targeting MTOR in glioblastoma: rationale and preclinical/clinical evidence., Dis Markers, № 2018, с. 9230479
     https://doi.org/10.1155/2018/9230479
101. Boni, Pharmaco*kinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications., J Clin Pharmacol, № 47, с. 1430
     https://doi.org/10.1177/0091270007306957
102. Pópulo, The MTOR signalling pathway in human cancer., Int J Mol Sci, № 13, с. 1886
     https://doi.org/10.3390/ijms13021886
103. Malizzia, Temsirolimus, an MTOR inhibitor for treatment of patients with advanced renal cell carcinoma., Clin J Oncol Nurs, № 12, с. 639
     https://doi.org/10.1188/08.CJON.639-646
104. Xu, Hematologic toxicities associated with MTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis., Curr Med Res Opin, № 30, с. 67
     https://doi.org/10.1185/03007995.2013.844116
105. Busaidy, The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab., Oncologist, № 20, с. 737
     https://doi.org/10.1634/theoncologist.2015-0065
106. Kwitkowski, FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma., Oncologist, № 15, с. 428
     https://doi.org/10.1634/theoncologist.2009-0178
107. Sener, Immunotherapy in glioblastoma: current approaches and future perspectives., Int J Mol Sci, № 23, с. 7046
     https://doi.org/10.3390/ijms23137046
108. Bausart, Immunotherapy for glioblastoma: the promise of combination strategies., J Exp Clin Cancer Res, № 41, с. 1
     https://doi.org/10.1186/s13046-022-02251-2

Дані публікації